←Back to Expert Scholars
Translational Medicine / 转化医学CLL Therapy, MRD Monitoring
Peter Hillmen
MB ChB, PhD
🏢University of Leeds🌐UK
Professor of Experimental Haematology
82
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Peter Hillmen led the CLARITY and FLAIR trials evaluating ibrutinib plus venetoclax combinations in chronic lymphocytic leukemia. His work advanced the use of minimal residual disease as a trial endpoint and guides time-limited therapy strategies. He remains a leader in UK and European CLL trial networks.
Share:
🧪Research Fields 研究领域
CLL
venetoclax
ibrutinib
MRD
CLARITY trial
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Peter Hillmen 的研究动态
Follow Peter Hillmen's research updates
留下邮箱，当我们发布与 Peter Hillmen（University of Leeds）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment